Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
FY2025 at a glance

Sales up 16.4%, free cash flow down to $93.9M

XBRL, from each 10-K
RevenueStatements
$738.3M from $634.4M in FY2024
FY2016FY2025
Net incomeStatements
$48.9M from -$25.5M in FY2024
FY2016FY2025
Free cash flowStatements
$93.9M from $149.7M in FY2024
FY2016FY2025
EPS (diluted)Statements
$0.86 from $-0.46 in FY2024
FY2016FY2025
Operating marginStatements
7.5% from -5.5% in FY2024
FY2016FY2025
Total debtStatements
$542.2M from $525.6M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (45)
EPS (ttm)
-0.21
Sales (ttm)
805.6M
Net income (ttm)
-11.8M
Sales growth
+16.4%
EPS growth
-
Sales Q/Q
+10.9%
Free cash flow
106.7M
Gross margin
53.5%
Oper. margin
2.3%
Net margin
-1.5%
FCF margin
13.2%
R&D / sales
7.3%
Dividend
-
Debt/Eq
0.27
Curr. ratio
9.88
Cash
727.0M
Op. cash flow (ttm)
129.9M
EBITDA
133.9M
EBITDA margin
18.1%
Net debt
-171.4M
Quick ratio
8.53
Interest cover
2.56
ROIC
1.6%
FCF after stock pay
61.3M
Debt / FCF (years)
5.92
Goodwill / assets
37.8%
Oper. margin low 5y
-5.5%
Tax rate
21.6%
Stock pay / sales
4.4%
Shares out.
63.9M
Shares Y/Y
+1.1%
Book / share
32.72
Cash / share
11.37
Sales / share
12.60
Asset turnover
0.28
Inventory turns
2.07
Days sales out.
78
Sales 3Y CAGR
-2.7%
Sales 5Y CAGR
+15.1%
EPS 3Y CAGR
-35.7%
EPS 5Y CAGR
-5.0%
Employees
2,000
Sales / employee
403K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 738.3M +24.3% a year Net income 48.9M +17.2% a year
FY2016 revenue 104.5M · Revenues, 0001193125-18-054262 FY2016 net income 11.7M · NetIncomeLoss, 0001193125-19-060645 104.5M FY2016 FY2017 revenue 141.2M · Revenues, 0001193125-18-054262 FY2017 net income 28.4M · NetIncomeLoss, 0001193125-20-050136 141.2M FY2017 FY2018 revenue 194.0M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-21-054675 FY2018 net income 16.6M · NetIncomeLoss, 0001193125-21-054675 194.0M FY2018 FY2019 revenue 270.2M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-22-001430 FY2019 net income 21.4M · NetIncomeLoss, 0000950170-22-001430 270.2M FY2019 FY2020 revenue 366.3M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-23-003793 FY2020 net income 59.9M · NetIncomeLoss, 0000950170-23-003793 366.3M FY2020 FY2021 revenue 670.5M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-24-127842 FY2021 net income 128.3M · NetIncomeLoss, 0000950170-24-127842 670.5M FY2021 FY2022 revenue 801.5M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-25-038999 FY2022 net income 186.0M · NetIncomeLoss, 0000950170-25-038999 801.5M FY2022 FY2023 revenue 632.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-076528 FY2023 net income 35.6M · NetIncomeLoss, 0001193125-26-076528 632.4M FY2023 FY2024 revenue 634.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-076528 FY2024 net income -25.5M · NetIncomeLoss, 0001193125-26-076528 634.4M FY2024 FY2025 revenue 738.3M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-076528 FY2025 net income 48.9M · NetIncomeLoss, 0001193125-26-076528 738.3M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
0 2000 4000 100 Revenue: $104.5M in FY2016, $738.3M in FY2025 REVENUE $738.3M · 7.1x Free cash flow: $3.2M in FY2016, $93.9M in FY2025 FREE CASH FLOW $93.9M · 29.4x FY2016 = 100FY2021FY2025
Revenue 7.1x $104.5M to $738.3M
Free cash flow 29.4x $3.2M to $93.9M

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +11.9% a year FY2015 $0.28 to FY2025 $0.86, 10 years
0 500000 1000000 100 Book value / share: $3.66 in FY2015, $37,236.42 in FY2025 BOOK VALUE / SHARE $37,236.42 · 10185.8x FCF / share: $0.37 in FY2015, $1,660.12 in FY2025 FCF / SHARE $1,660.12 · 4486.3x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.86$37,236.42$1,660.12
Dec 31, 2024 -$0.46$35,266.78$2,676.53
Dec 31, 2023 $0.63$34,851.89$1,378.15
Dec 31, 2022 $3.24$33,255.59$1,518.56
Dec 31, 2021 $2.24$30,561.38$906.80
Dec 31, 2020 $1.11$28,374.34$745.38
Dec 31, 2019 $0.44$21.54$0.99
Dec 31, 2018 $0.37$13.54$0.49
Dec 31, 2017 $0.72$15.11$0.31
Dec 31, 2016 $0.34$4,949.24$93.73
Dec 31, 2015 $0.28$3.66$0.37

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.1B
  • − All liabilities $843.6M
  • = Net current asset value $293.8M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $2.1B
  • − Goodwill $1.1B
  • − Other intangible assets $386.1M
  • = Tangible book value $605.6M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

RGEN against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+16.4%51st of 155 · median +10.5%
Net margin
-4.1%15.3%
-1.5%112th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-0.6%103rd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
13.2%60th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.2721st of 108 · median 0.69
RGEN and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
RGEN Repligen Corp$805.6M +16.4%53.5%-1.5%-0.6%13.2%0.27
INSP Inspire Medical Systems, Inc.$880.9M +13.6%86.2%11.4%12.2%11.1%-
AXSM Axsome Therapeutics, Inc.$865.3M +65.5%--18.2%-149.2%-9.5%1.78
SUPN Supernus, Inc.$865.1M +8.6%87.6%-5.1%-4.1%10.1%-
IRTC iRhythm Holdings, Inc.$854.0M +26.2%72.3%-4.5%-21.8%0.9%-
RARE Ultragenyx Pharmaceutical Inc.$730.0M +20.2%--71.8%--60.5%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $670.5M of sales to $128.3M of profit FY2021

  • Royalty and Other Revenue $215K
  • Products $670.3M
Revenue to Gross profit: $391.3MRevenue to Cost of revenue: $279.3MGross profit to Operating profit: $167.2MGross profit to Operating expenses: $224.0MOperating profit to Net profit: $128.3MOperating profit to Tax & other: $39.0MOperating expenses to R&D: $34.3MOperating expenses to Sales, admin & other: $189.7M Revenue: $670.5M REVENUE $670.5M +83% Y/Y Gross profit: $391.3M · 58% margin GROSS PROFIT $391.3M 58% margin Cost of revenue: $279.3M · 42% of revenue COST OF REVENUE $279.3M 42% of revenue Operating profit: $167.2M · 25% margin OPERATING PROFIT $167.2M 25% margin · +140% Y/Y Operating expenses: $224.0M · 33% of revenue OPERATING EXPENSES $224.0M 33% of revenue Net profit: $128.3M · 19% margin NET PROFIT $128.3M 19% margin · +114% Y/Y Tax & other: $39.0M · 6% of revenue TAX & OTHER $39.0M 6% of revenue R&D: $34.3M · 5% of revenue R&D $34.3M 5% of revenue Sales, admin & other: $189.7M · 28% of revenue SALES, ADMIN & OTHER $189.7M 28% of revenue

From $801.5M of sales to $186.0M of profit FY2022

  • Filtration Products $495.9M
  • Chromatography Products $131.7M
  • Proteins Products $114.3M
  • Process Analytics Products $53.5M
  • Other products $5.7M
  • Royalty and Other Revenue $353K
Revenue to Gross profit: $455.7MRevenue to Cost of revenue: $345.8MGross profit to Operating profit: $224.7MGross profit to Operating expenses: $231.0MOperating profit to Net profit: $186.0MOperating profit to Tax & other: $38.7MOperating expenses to R&D: $43.9MOperating expenses to Sales, admin & other: $187.1M Revenue: $801.5M REVENUE $801.5M +20% Y/Y Gross profit: $455.7M · 57% margin GROSS PROFIT $455.7M 57% margin Cost of revenue: $345.8M · 43% of revenue COST OF REVENUE $345.8M 43% of revenue Operating profit: $224.7M · 28% margin OPERATING PROFIT $224.7M 28% margin · +34% Y/Y Operating expenses: $231.0M · 29% of revenue OPERATING EXPENSES $231.0M 29% of revenue Net profit: $186.0M · 23% margin NET PROFIT $186.0M 23% margin · +45% Y/Y Tax & other: $38.7M · 5% of revenue TAX & OTHER $38.7M 5% of revenue R&D: $43.9M · 5% of revenue R&D $43.9M 5% of revenue Sales, admin & other: $187.1M · 23% of revenue SALES, ADMIN & OTHER $187.1M 23% of revenue

From $632.4M of sales to $35.6M of profit FY2023

  • Filtration Products $341.4M
  • Chromatography Products $126.6M
  • Proteins Products $103.5M
  • Process Analytics Products $56.8M
  • Other products $3.7M
  • Royalty and Other Revenue $383K
Revenue to Gross profit: $278.4MRevenue to Cost of revenue: $353.9MGross profit to Operating profit: $47.7MGross profit to Operating expenses: $230.7MOperating profit to Net profit: $26.6MOperating profit to Tax: $21.1MOther income to Net profit: $9.0MOperating expenses to R&D: $42.7MOperating expenses to Sales, admin & other: $188.0M Revenue: $632.4M REVENUE $632.4M −21% Y/Y Gross profit: $278.4M · 44% margin GROSS PROFIT $278.4M 44% margin Cost of revenue: $353.9M · 56% of revenue COST OF REVENUE $353.9M 56% of revenue Operating profit: $47.7M · 8% margin OPERATING PROFIT $47.7M 8% margin · −79% Y/Y Other income: $9.0M · 1% of revenue OTHER INCOME $9.0M 1% of revenue Operating expenses: $230.7M · 36% of revenue OPERATING EXPENSES $230.7M 36% of revenue Net profit: $35.6M · 6% margin NET PROFIT $35.6M 6% margin · −81% Y/Y Tax: $21.1M · 3% of revenue TAX $21.1M 3% of revenue R&D: $42.7M · 7% of revenue R&D $42.7M 7% of revenue Sales, admin & other: $188.0M · 30% of revenue SALES, ADMIN & OTHER $188.0M 30% of revenue

From $738.3M of sales to $48.9M of profit FY2025

  • Filtration Products $402.8M
  • Chromatography Products $153.2M
  • Proteins Products $97.4M
  • Process Analytics Products $81.2M
  • Other products $3.3M
  • Royalty and Other Revenue $296K
Revenue to Gross profit: $386.2MRevenue to Cost of revenue: $352.0MGross profit to Operating profit: $55.2MGross profit to Operating expenses: $331.1MOperating profit to Net profit: $48.9MOperating profit to Tax & other: $6.3MOperating expenses to R&D: $54.2MOperating expenses to Sales, admin & other: $276.9M Revenue: $738.3M REVENUE $738.3M +16% Y/Y Gross profit: $386.2M · 52% margin GROSS PROFIT $386.2M 52% margin Cost of revenue: $352.0M · 48% of revenue COST OF REVENUE $352.0M 48% of revenue Operating profit: $55.2M · 7% margin OPERATING PROFIT $55.2M 7% margin Operating expenses: $331.1M · 45% of revenue OPERATING EXPENSES $331.1M 45% of revenue Net profit: $48.9M · 7% margin NET PROFIT $48.9M 7% margin Tax & other: $6.3M · 1% of revenue TAX & OTHER $6.3M 1% of revenue R&D: $54.2M · 7% of revenue R&D $54.2M 7% of revenue Sales, admin & other: $276.9M · 38% of revenue SALES, ADMIN & OTHER $276.9M 38% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 2.3% FY2020: 3.9% net income ÷ equity
Net margin 6.6% FY2020: 16.4% profit per $ of sales: 48.9M ÷ 738.3M
Asset turnover 0.25× FY2020: 0.19× sales per $ of assets: 738.3M ÷ 2.9B
Leverage 1.40× FY2020: 1.24× assets per $ of equity: 2.9B ÷ 2.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -1.5% vs 6.8%
  • Return on equity below 15%
    -0.6%
  • A profit in 9 of 10 years
Net margin, FY2016 to FY2025: 11.2% to 6.6%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 2.6× interest expense
  • Debt smaller than equity
    Debt / equity 0.27 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 9.88
  • More cash than debt
    Net cash $373.0M
Debt / equity at each year end, FY2016 to FY2025: 0.27 to 0.26

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $93.9M last year
  • Share count up over 5 years
    +5.0%
  • Cash from operations above net income
    $117.4M vs $48.9M
Free cash flow, FY2016 to FY2025: 3.2M to 93.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $18.9M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +15.5% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

RGEN's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue738.3M
FY2016: 104.5MFY2017: 141.2MFY2018: 194.0MFY2019: 270.2MFY2020: 366.3MFY2021: 670.5MFY2022: 801.5MFY2023: 632.4MFY2024: 634.4MFY2025: 738.3M FY2017FY2019FY2021FY2023FY2025
Net income48.9M
FY2016: 11.7MFY2017: 28.4MFY2018: 16.6MFY2019: 21.4MFY2020: 59.9MFY2021: 128.3MFY2022: 186.0MFY2023: 35.6MFY2024: -25.5MFY2025: 48.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow93.9M
FY2016: 3.2MFY2017: 12.0MFY2018: 22.1MFY2019: 48.7MFY2020: 40.2MFY2021: 51.9MFY2022: 87.2MFY2023: 77.7MFY2024: 149.7MFY2025: 93.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay61.3M
FY2016: -1.4MFY2017: 5.2MFY2018: 11.9MFY2019: 35.9MFY2020: 23.2MFY2021: 24.4MFY2022: 59.9MFY2023: 52.1MFY2024: 101.6MFY2025: 61.3M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)0.86
FY2016: 0.34FY2017: 0.72FY2018: 0.37FY2019: 0.44FY2020: 1.11FY2021: 2.24FY2022: 3.24FY2023: 0.63FY2024: -0.46FY2025: 0.86 FY2017FY2019FY2021FY2023FY2025
Diluted shares57K
FY2016: 34KFY2017: 39.1MFY2018: 45.5MFY2019: 49.2MFY2020: 54KFY2021: 57KFY2022: 57KFY2023: 56KFY2024: 56KFY2025: 57K FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Filtration Products 402.8M54.6% +8.0%
Chromatography Products 153.2M20.7% +24.7%
Proteins Products 97.4M13.2% +30.9%
Process Analytics Products 81.2M11.0% +37.0%
Other products 3.3M0.4% -29.0%
Royalty and Other Revenue 296K0.0% +13.4%

10-K 0001193125-26-076528, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue104.5M141.2M194.0M270.2M366.3M670.5M801.5M632.4M634.4M738.3M
Cost of revenue47.1M67.0M86.5M119.1M156.6M279.3M345.8M353.9M359.8M352.0M
R&D7.4M8.7M15.8M19.4M20.2M34.3M43.9M42.7M43.2M54.2M
SG&A30.9M51.5M65.7M95.6M119.6M183.9M215.8M218.6M263.4M290.5M
Operating income16.0M14.0M26.0M36.1M69.8M167.2M224.7M47.7M-35.1M55.2M
Interest expense3.8M6.4M6.7M9.3M10.8M11.3M1.2M2.0M20.7M21.5M
Pretax income11.7M7.2M21.4M26.2M59.2M153.5M219.1M56.7M-27.0M62.4M
Income tax11K-21.1M4.8M4.7M-709K25.3M33.2M21.1M-1.5M13.5M
Net income11.7M28.4M16.6M21.4M59.9M128.3M186.0M35.6M-25.5M48.9M
EPS (diluted)0.340.720.370.441.112.243.240.63-0.460.86
Diluted shares34K39.1M45.5M49.2M54K57K57K56K56K57K
Depreciation & amortization5.3M10.5M15.8M20.9M27.1M38.4M51.0M68.6M69.7M78.7M
EBITDA21.3M24.5M41.8M57.0M96.9M205.7M275.7M116.3M34.6M133.9M
Operating margin15.3%9.9%13.4%13.4%19.1%24.9%28.0%7.5%-5.5%7.5%
Net margin11.2%20.1%8.6%7.9%16.4%19.1%23.2%5.6%-4.0%6.6%
Revenue growth+25.1%+35.1%+37.4%+39.3%+35.5%+83.1%+19.5%-21.1%+0.3%+16.4%
EPS growth+21.4%+112%-48.6%+18.9%+152%+102%+44.6%-80.6%to a loss-

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow7.5M17.5M32.8M67.2M62.6M119.0M172.1M113.9M175.4M117.4M
Capital spending4.3M5.5M10.6M18.5M22.5M67.1M84.8M36.2M25.7M23.5M
Free cash flow3.2M12.0M22.1M48.7M40.2M51.9M87.2M77.7M149.7M93.9M
Stock-based pay (added back)4.6M6.7M10.2M12.8M17.0M27.5M27.3M25.6M48.1M32.6M
Free cash flow after stock pay-1.4M5.2M11.9M35.9M23.2M24.4M59.9M52.1M101.6M61.3M
Buybacks-----0014.4M00
Acquisitions44.6M112.8M-182.2M175.0M149.9M0186.6M54.8M70.3M
Investing cash flow-49.2M-98.7M-14.0M-205.3M-201.4M-221.2M-233.2M-123.3M-86.4M-298.5M
Financing cash flow112.1M129.9M3.4M484.9M305.9M961K-13.3M249.0M-82.9M-15.2M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)4.6M6.7M10.2M12.8M17.0M27.5M27.3M25.6M48.1M32.6M
Stock-based pay / revenue4.4%4.8%5.3%4.8%4.6%4.1%3.4%4.0%7.6%4.4%
Operating lease cost---4.5M5.6M9.8M17.8M21.0M24.2M25.2M
Operating lease cash paid---4.0M5.6M8.9M13.8M17.9M23.8M25.8M
Right-of-use assets---25.7M25.2M101.6M125.0M115.5M135.4M119.5M
Operating lease liabilities---30.6M31.7M110.8M138.3M132.2M160.7M147.7M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.